Cristal Therapeutics raises additional funding

Date: 01/07/2013

1 July 2013, Maastricht and Utrecht – Cristal Therapeutics, the new trade name of the Dutch nanomedicine company Cristal Delivery B.V., announces the successful expansion of the financing round initiated by Thuja Capital and BioGeneration Ventures, by adding two additional investors, being Nedermaas Ventures and Innovatie Fonds Limburg. The proceeds of this round will allow Cristal Therapeutics to progress CriPec® docetaxel as first product into clinical development. Besides, the headquarter of Cristal Therapeutics will relocate from Utrecht to Maastricht.

Plase find the original press release here.